Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.
Trial Parameters
Brief Summary
ActiCIDP is a monocentric academic study. Patients with Chronic inflammatory demyelinating polyradiculoneuritis may be included on a voluntary basis. The investigators plan to include a group of approximately 40 patients with CIDP. The investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with CIDP or possible CIDP based on 2021 EAN/PNS criteria2. * Treated with IVIg (≤1g/kg/3-8week) * Clinically Stable disease for 3 months (according to treating physician opinion). * No treatment withdrawal failure within 1 year * Age over 18 years Exclusion Criteria: * Significant cognitive or communication disorders * Surgery or serious traumatic injury ≤ 6 months * Non ambulant patient * Current participation to a therapeutic trial * Anti-myeline antibodies (anti-MAG) positive or nodo-paranodopathy * Other autoimmune disease that requires Corticosteroids, IVIg, Plasma Exchange treatment * Pregnancy or breastfeeding * Any other condition that, according to the investigator, could significantly interfere with patient evaluation or safety.